Graphite Bio
LENZ Therapeutics is developing Aceclidine-based ophthalmic solutions to treat presbyopia, a condition affecting nearly 2 billion people worldwide by causing the loss of near vision. Their lead program aims to restore near vision, providing a potential alternative to reading glasses for a broad patient population.
- Biotechnology
Funding
Raised to date
$30MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Presbyopia, the age-related loss of near vision, affects nearly two billion people worldwide, often requiring the use of reading glasses or other vision aids. Current solutions can be inconvenient or have limitations in addressing the underlying cause of the condition.
Solution
LENZ Therapeutics is developing Aceclidine-based ophthalmic pharmaceutical products designed to improve near vision for individuals with presbyopia. Their lead program focuses on restoring the ability to see clearly at close distances, potentially reducing or eliminating the need for reading glasses. The company's approach aims to provide a convenient and effective treatment option for a broad range of patients experiencing age-related vision decline. By targeting the physiological mechanisms behind presbyopia, LENZ Therapeutics seeks to offer a more comprehensive solution compared to traditional corrective lenses.
Target Audience
The primary target audience includes individuals experiencing presbyopia, specifically those seeking an alternative or adjunct to reading glasses for improved near vision.
Features
- Aceclidine-based formulation for optimal efficacy and safety
- Designed for easy self-administration as an eye drop
- Clinical-stage development program with ongoing trials
- Potential to improve near vision without affecting distance vision